Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TYMP | P19971 | 3/20 | 0.37 |
| ▸ | CA12 | O43570 | 5/20 | 0.36 |
| ▸ | CA1 | P00915 | 5/20 | 0.36 |
| ▸ | CA2 | P00918 | 5/20 | 0.36 |
| ▸ | CA9 | Q16790 | 5/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Misonidazole SCHEMBL51943 | 0.91 | KMT2A (0.66) | KMT2ALMNATHRBCYP2C19HPGD | |
| Misonidazole SCHEMBL18770100 | 0.80 | KMT2A (0.54) | KMT2ALMNATHRBCYP2C19HPGD | |
| Misonidazole SCHEMBL14128122 | 0.79 | KMT2A (0.48) | KMT2ALMNATHRBCYP2C19HPGD | |
| SCHEMBL12396375 | 0.78 | KMT2A (0.78) | KMT2ALMNATHRBCYP2C19HPGD | |
| Misonidazole SCHEMBL2833961 | 0.78 | KMT2A (0.51) | KMT2ALMNATHRBCYP2C19HPGD | |
| Misonidazole SCHEMBL9762481 | 0.78 | KMT2A (0.51) | KMT2ALMNATHRBCYP2C19HPGD | |
| Mitindomide SCHEMBL16861169 | 0.77 | KMT2A (0.51) | KMT2ALMNATHRBCYP2C19HPGD | |
| SCHEMBL9441423 | 0.77 | KMT2A (0.62) | KMT2ALMNATHRBCYP2C19HPGD | |
| SCHEMBL6275185 | 0.77 | KMT2A (0.55) | KMT2ALMNATHRBCYP2C19HPGD | |
| SCHEMBL16367290 | 0.76 | KMT2A (0.60) | KMT2ALMNATHRBCYP2C19HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2340837-A1 | Combination treatment of cancer comprising EGFR/HER2 inhibitors | Boehringer Ingelheim International GmbH (DE) | 2011-07-06 | — | — | EP | claimed |
| US-20090306101-A1 | COMBINATION TREATMENT OF CANCER COMPRISING EGFR/HER2 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-10 | — | — | US | claimed |
| EP-1948180-A1 | COMBINATION TREATMENT OF CANCER COMPRISING EGFR/HER2 INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2008-07-30 | — | — | EP | claimed |
| WO-2007054551-A1 | COMBINATION TREATMENT OF CANCER COMPRISING EGFR/HER2 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-18 | — | — | WO | claimed |
| US-20230063457-A1 | DNA-PK INHIBITING COMPOUNDS | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2023-03-02 | — | — | US | disclosed |
| EP-4028398-A1 | DNA-PK INHIBITING COMPOUNDS | Provincial Health Services Authority (CA) | 2022-07-20 | — | — | EP | disclosed |
| WO-2021050059-A1 | DNA-PK INHIBITING COMPOUNDS | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2021-03-18 | — | — | WO | disclosed |
| US-9944633-B2 | Compounds and methods for the treatment of isocitrate dehydrogenase related diseases | THE BROAD INSTITUTE, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20160102087-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF ISOCITRATE DEHYDROGENASE RELATED DISEASES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2016-04-14 | — | — | US | disclosed |
| EP-2759538-B1 | RADIOACTIVE FLUORINE LABELED COMPOUND | NIHON MEDIPHYSICS CO LTD (JP) | 2016-03-23 | — | — | EP | disclosed |
| US-9120810-B2 | Compounds and methods for the treatment of isocitrate dehydrogenase related diseases | THE BOARD INSTITUTE, INC. (US) | 2015-09-01 | — | — | US | disclosed |
| US-9107964-B2 | Radioactive fluorine-labeled compound | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2015-08-18 | — | — | US | disclosed |
| EP-2691391-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF ISOCITRATE DEHYDROGNASE RELATED DISEASES | The Broad Institute, Inc. (US) | 2014-02-05 | — | — | EP | disclosed |
| WO-2013042668-A1 | RADIOACTIVE FLUORINE LABELED COMPOUND | 日本メジフィジックス株式会社 (JP) | 2013-03-28 | — | — | WO | disclosed |
| WO-2013032907-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER STEM CELLS | THE BROAD INSTITUTE, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| WO-2012173682-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF ISOCITRATE DEHYDROGNASE RELATED DISEASES | THE BROAD INSTITUTE, INC. (US) | 2012-12-20 | — | — | WO | disclosed |
| WO-2005030137-A2 | IMPROVING BIOMECHANICAL PERFORMANCE OF IRRADIATED BIOLOGICAL MATERIAL | THE UNIVERSITY OF TOLEDO, A UNIVERSITY INSTRUMENTALITY OF THE STATE OF OHIO (US) | 2005-04-07 | — | — | WO | disclosed |
| US-6855828-B1 | Detection of hypoxia | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2005-02-15 | — | — | US | disclosed |
| US-20050026974-A1 | Detection of hypoxia | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2005-02-03 | — | — | US | disclosed |
| US-6252087-B1 | COMPLEXING WITH A PROTEIN | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2001-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026974-A1 | Detection of hypoxia | HIF1A, HIF1AN, HYOU1 | KMT2A 877/4885LMNA 4407/4885THRB 3873/4885 |
| US-20160102087-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF ISOCITRATE DEHYDROGENASE RELATED DISEASES | IDH1, IDH2, IDH3A | KMT2A 1147/4885LMNA 2361/4885THRB 2209/4885 |
| US-20230063457-A1 | DNA-PK INHIBITING COMPOUNDS | DCK, POLK, ERCC2 | KMT2A 1271/4885LMNA 1168/4885THRB 2916/4885 |
| US-20090306101-A1 | COMBINATION TREATMENT OF CANCER COMPRISING EGFR/HER2 INHIBITORS | EGFR, ERBB2, ERBB3 | KMT2A 1114/4885LMNA 4846/4885THRB 999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.